2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. SGK
  5. SGK1 Isoform
  6. SGK1 Inhibitor

SGK1 Inhibitor

SGK1 Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-15192
    GSK 650394
    		Inhibitor 99.76%
    GSK 650394 is a novel SGK inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits influenza virus replication.
  • HY-15193
    EMD638683
    		Inhibitor 99.89%
    EMD638683 is a highly selective SGK1 inhibitor, with an IC50 value of 3 μM.
  • HY-18607
    SGK1-IN-1
    		Inhibitor 99.67%
    SGK1-IN-1 is a highly active and selective inhibitor of SGK-1, with an IC50 of 1 nM.
  • HY-142686
    SGK1-IN-3
    		Inhibitor
    SGK1-IN-3 (compound 3a) is a potent and orally active inhibitor of SGK1. The serine/threonine kinase SGK1 is an activator of the β-catenin pathway and a powerful stimulator of cartilage degradation that is found to be upregulated under genomic control in diseased osteoarthritic cartilage. SGK1-IN-3 has the potential for the research of osteoarthritis.
  • HY-167832
    PT109
    		Inhibitor
    PT109 is a multi-kinase inhibitor. PT109 inhibits JNK (JNK1: IC50=0.143 μM; JNK2: IC50=0.831 μM; JNK3: IC50=0.285 μM) and other kinases (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM; ROCK2: IC50=34 μM) and plays an important role in anti-inflammation, anti-oxidation, neurogenesis, synaptogenesis, etc. In addition, PT109 also reprograms glioblastoma multiforme (GBM) into oligodendrocytes through the PTBP1/PKM1/2 pathway and changes the metabolic pattern of GBM, exerting anti-glioma activity.